Release of high levels of IL-11 from breast tumors is strongly correlated with an increased probability of developing bone metastases [64], while higher circulating serum levels of IL-6 are associated with the presence of >1 metastatic site and with liver metastasis, which occurs in advanced metastatic disease [65]. Here, IL11 is linked to metastatic neoplasm.